The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

The report from techUK welcomes the new Labour government's recognition that "decisive change" – underpinned by digital ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-elect has ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking. On the plus side ...

Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA. Shares in the company gained almost ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

Today, we live in an age of artificial intelligence (AI); more specifically, the age of generative AI (GenAI). In a recent report, 65% of respondents stated that their organisations are regularly ...

Drug manufacturers, wholesale distributors and pharmacies stepped up during the COVID-19 pandemic to preserve supply chain integrity. They were very particular about quality because the stakes ...

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

Leela Barham looks at the first operational review meeting minutes that have been published on the VPAG, the UK’s latest scheme on branded medicines pricing and access, building on previous work ...